Alzheimer’s disease (AD) is said to be the most common form of dementia. It is a progressive and neurodegenerative disease resulting in cognitive functions loss. The current status of the disease is that it is incurable. It is characterized by loss of memory and other mental abnormalities. AD has an adverse impact on independence and quality of life, with people suffering from it requiring full-time care in the later stages of the disease. Besides cognitive impairment, it is also associated with psychological and behavioral changes, which are often the primary challenges for patients and caregivers.
The cases of Alzheimer’s disease are increasing rapidly, primarily due to the expanding base of geriatrics across the world, since aging is the foremost epidemiological risk factor for the disease. There are large unmet needs in AD and the psychological and behavioral complications are contributing tremendously to the disease burden. This is leading to high levels of research and development investments over the last two decades, however, the treatment options remain limited due to various factors. These factors include stringent government regulations, which delay the approval time for AD therapeutics. Besides this, the high rates of failure of clinical trials, especially in last stages, coupled with the expiry of several patent drugs are limiting the widespread availability of treatment options.
In present times, there are no disease-modifying therapies for Alzheimer’s disease, and approaches used can only temporarily slow down the worsening of symptoms. However, the growing government funding towards healthcare and the rising consumer awareness are likely to promote development and innovation of new drugs to treat, slow, and prevent AD. Currently, the pipeline pertaining to the disease’s therapeutics is large and includes a remarkable proportion of first-in-class product innovation.
North America and Europe are expected to be prominent markets for Alzheimer’s disease owing to the rapidly growing geriatric population. India and China will be sights of high growth rate in Asia Pacific. The growth of emerging nations can be attributed to the improving healthcare infrastructure and increasing investments in research and development. Some of the prominent participants in the global Alzheimer’s disease market are Merck & Co. Inc., F. Hoffmann-La Roche Ltd., Novartis AG., Pfizer Inc., Actavis, Eisai Co. Ltd., Transtech Pharma, Daiichi Sankyo, and H. Lundbeck A/S.